Fig 1: C-82 significantly reduces the protein expression level of MCL-1 by disrupting the stability of MCL-1 protein when used alone or in combination with VEN. A,B AML cell lines were treated with C-82 alone or in combination with VEN for 24 h, and Western blotting and RT-qPCR were used to detect the protein and mRNA expression levels of MCL-1, BCL-2 and BCL-xL. C,D AML cell lines were treated with C-82 at different time periods, and the mRNA and protein expression levels of MCL-1 were detected by RT-qPCR and Western blotting. E AML cell lines were treated with CHX (10 μg/ml) with or without C-82 (MOLM13; 600 nm, NOMO1; 300 nM) at indicated time points, and Western blotting was performed to detect the protein expression levels of MCL-1. F AML cell lines were pretreated or not pretreated with 1 μM MG-132 for 4 h and then treated with C-82 (MOLM13; 600 nM; NOMO1; 300 nM) for 2 h. G AML cell lines were pretreated or not pretreated with 0.8 μM MG-132 for 2 h and then treated with C-82 (MOLM13; 500 nM, NOMO1; 300 nM) for 1 h, ubiquitination analysis of the ubiquitinated MCL-1 level by using Western blotting